Abstract
Psychiatry is a specialty where the application of pharmacogenomics approaches is made to the study of interindividual differences in response to antidepressants. It is highly applied for improving patient treatment. Major depressive disorder (MDD) is a common and complex disorder resulting from genetic and environmental interactions. Less than 40% of patients with MDD achieve remission, and even after several treatment trials, one in three patients do not fully recover from MDD. Many clinical and genomic association studies suggested that the catechol-Omethyltransferase (COMT) gene region was an important genetic locus for psychiatric disorders, because of the proposed relationship between its function in catecholaminergic neurotransmission and individual response to antidepressants, and vulnerability to psychiatric disorders. Although a number of COMT single nucleotide polymorphisms (SNPs) were observed, the Val108/158Met (rs4680) polymorphism in exon 4 resulted in a change in the enzyme structure which has been intensively investigated in relation to its role of enzyme activity and processes of prefrontal cortex functions in cognition. As serotonin interacts with dopamine and dopamine availability is influenced by COMT SNPs, an association between the COMT gene and response to treatment, based on the various pharmacogenetics/pharmacogenomics studies about COMT gene published to date, is explored in this overview.
Keywords: COMT gene, pharmacogenetics, antidepressant, treatment response, snp, Catechol O Methyl Transferase, Major Depressive disorder , COMT, MDD, rs4680, Antidepressant treatment, Dopamine
CNS & Neurological Disorders - Drug Targets
Title:Catechol-O-Methyltransferase (COMT) Pharmacogenetics in the Treatment Response Phenotypes of Major Depressive Disorder (MDD)
Volume: 11 Issue: 3
Author(s): Neslihan Aygun Kocabas
Affiliation:
Keywords: COMT gene, pharmacogenetics, antidepressant, treatment response, snp, Catechol O Methyl Transferase, Major Depressive disorder , COMT, MDD, rs4680, Antidepressant treatment, Dopamine
Abstract: Psychiatry is a specialty where the application of pharmacogenomics approaches is made to the study of interindividual differences in response to antidepressants. It is highly applied for improving patient treatment. Major depressive disorder (MDD) is a common and complex disorder resulting from genetic and environmental interactions. Less than 40% of patients with MDD achieve remission, and even after several treatment trials, one in three patients do not fully recover from MDD. Many clinical and genomic association studies suggested that the catechol-Omethyltransferase (COMT) gene region was an important genetic locus for psychiatric disorders, because of the proposed relationship between its function in catecholaminergic neurotransmission and individual response to antidepressants, and vulnerability to psychiatric disorders. Although a number of COMT single nucleotide polymorphisms (SNPs) were observed, the Val108/158Met (rs4680) polymorphism in exon 4 resulted in a change in the enzyme structure which has been intensively investigated in relation to its role of enzyme activity and processes of prefrontal cortex functions in cognition. As serotonin interacts with dopamine and dopamine availability is influenced by COMT SNPs, an association between the COMT gene and response to treatment, based on the various pharmacogenetics/pharmacogenomics studies about COMT gene published to date, is explored in this overview.
Export Options
About this article
Cite this article as:
Aygun Kocabas Neslihan, Catechol-O-Methyltransferase (COMT) Pharmacogenetics in the Treatment Response Phenotypes of Major Depressive Disorder (MDD), CNS & Neurological Disorders - Drug Targets 2012; 11 (3) . https://dx.doi.org/10.2174/187152712800672445
DOI https://dx.doi.org/10.2174/187152712800672445 |
Print ISSN 1871-5273 |
Publisher Name Bentham Science Publisher |
Online ISSN 1996-3181 |
Call for Papers in Thematic Issues
Diagnosis and treatment of central nervous system infectious diseases
Infectious diseases of the central nervous system (CNS) can be divided into bacterial, tuberculous, viral, fungal, parasitic infections, etc. Early etiological treatment is often the most crucial means to reduce the mortality rate of patients with central nervous system infections, reduce complications and sequelae, and improve prognosis. The initial clinical ...read more
Trends and perspectives in the rational management of CNS disorders
Central nervous system (CNS) diseases enforce a significant global health burden, driving ongoing efforts to improve our understanding and effectiveness of therapy. This issue investigates current advances in the discipline, focusing on the understanding as well as therapeutic handling of various CNS diseases. The issue covers a variety of diseases, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Lipid Transmitter Signaling as a New Target for Treatment of Cocaine Addiction: New Roles for Acylethanolamides and Lysophosphatidic Acid
Current Pharmaceutical Design Bioinformatic Application in Proteomic Research on Biomarker Discovery and Drug Target Validation
Current Bioinformatics Depressed Glucose Consumption at Reperfusion following Brain Ischemia does not Correlate with Mitochondrial Dysfunction and Development of Infarction: An in vivo Positron Emission Tomography Study
Current Neurovascular Research Does A Subclinical Cardiotoxic Effect of Clozapine Exist? Results from a Follow-up Pilot Study
Cardiovascular & Hematological Agents in Medicinal Chemistry Impact of the Presence of Select Cardiovascular Risk Factors on Cognitive Changes among Dementia Subtypes
Current Alzheimer Research Meet Our Editorial Board Member
CNS & Neurological Disorders - Drug Targets Selective Cholinesterase Inhibitors from Buxus sempervirens L. and their Molecular Docking Studies
Current Computer-Aided Drug Design G-Quadruplex Interacting Agents Targeting the Telomeric G-Overhang Are More than Simple Telomerase Inhibitors
Current Medicinal Chemistry - Anti-Cancer Agents Use of Atypical Antipsychotics as Mono/Polytherapy with Mood Stabilizers for the Treatment of Bipolar Disorder. An Update
Current Psychopharmacology Recent Advances in Nanotechnology: A Novel Therapeutic System for the Treatment of Alzheimer’s Disease
Current Drug Metabolism SELDI Protein Chip Technology for the Detection of Serum Biomarkers for Liver Disease
Protein & Peptide Letters Graphical Abstracts
Current Pharmaceutical Analysis Inflammatory Process as a Determinant Factor for the Degeneration of Substantia Nigra Dopaminergic Neurons: Possible Relevance to the Etiology of Parkinsons Disease
Current Medicinal Chemistry - Central Nervous System Agents Consequences of Secondary Hyperparathyroidism on Vascular Calcification and Cardiovascular Mortality: Potential Benefit of Calcimimetics
Current Drug Therapy Interventions Against Sarcopenia in Older Persons
Current Pharmaceutical Design Cruciferous Plants: Phytochemical Toxicity Versus Cancer Chemoprotection
Mini-Reviews in Medicinal Chemistry The Anti-Inflammatory and Pharmacological Actions of Oleocanthal, a Phenolic Contained in Extra Virgin Olive Oil
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Environment, Physical Activity, and Neurogenesis: Implications for Prevention and Treatment of Alzhemiers Disease
Current Alzheimer Research Withdrawal Notice: Drug Repurposing for Prospective Anti-Cancer Agents Along with the Clinical Status of the Repurposed Drug
Anti-Cancer Agents in Medicinal Chemistry Oxytocin as a Potential Adjuvant Against COVID-19 Infection
Endocrine, Metabolic & Immune Disorders - Drug Targets